Pacific Biosciences of California, Inc. (PACB)
Pacific Biosciences of California, Inc. (PACB) Q4 2024 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance and Investor Relations Christian Henry - President and CEO Michele Farmer - Chief Accounting Officer Conference Call Participants Tycho Peterson - Jefferies Kyle Mikson - Canaccord Dan Brennan - TD Cowen Doug Schenkel - Wolfe Research Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Subbu Nambi - Guggenheim Sung Ji Nam - Scotia Bank Mason Carrico - Stephens Operator Good day. And welcome to the PacBio Fourth Quarter 2024 Earnings Conference Call.
Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.27 per share a year ago.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.44, representing a -1.37% change from its previous close.
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
PACB Stock Declines Despite Promising HiFi Sequencing Findings
PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped
PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.
PacBio Stock May Gain Following the Collaborated Launch of GutID
PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test.
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics
PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets.
Why the Market Dipped But Pacific Biosciences of California (PACB) Gained Today
Pacific Biosciences of California (PACB) closed at $2 in the latest trading session, marking a +0.5% move from the prior day.
Reasons to Retain PacBio Stock in Your Portfolio for Now
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight
Ark Invest CEO Cathie Wood is doubling down on genomics.
